Philippe Dessen
YOU?
Author Swipe
View article: Supplementary Data from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation
Supplementary Data from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation Open
Supplementary figures and legends
View article: Supplementary Table S16 from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation
Supplementary Table S16 from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation Open
Gene set enrichment analysis (GSEA) comparing SPI1 WT (n = 29) versus QE (n = 3) WM RNAseq samples (MSigDB database) (H, hallmark gene sets)
View article: Data from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation
Data from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation Open
The ETS-domain transcription factors divide into subfamilies based on protein similarities, DNA-binding sequences, and interaction with cofactors. They are regulated by extracellular clues and contribute to cellular processes, including pr…
View article: Supplementary Table S15 from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation
Supplementary Table S15 from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation Open
Gene set enrichment analysis (GSEA) from RNA-seq obtained upon SPI1 WT (n = 3) and QE (n = 3) expression in OCI-Ly10 cells (Lymphochip database)
View article: Supplementary Tables S1-S14 and S17 from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation
Supplementary Tables S1-S14 and S17 from A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation Open
Supplementary tables
View article: Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers
Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers Open
The human leukocyte antigen (HLA) system is a major factor controlling cancer immunosurveillance and response to immunotherapy, yet its status in pediatric cancers remains fragmentary. We determined high-confidence HLA genotypes in 576 chi…
View article: A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors Open
Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date,…
View article: Supplementary Table S1 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Supplementary Table S1 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Open
Supplementary Table S1
View article: Supplementary Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Supplementary Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Open
This file contains supplementary Figures
View article: Supplementary Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Supplementary Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Open
This file contains supplementary Figures
View article: Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Open
Immune resistance may arise from both genetic instability and tumor heterogeneity. Microenvironmental stresses such as hypoxia and various resistance mechanisms promote carcinoma cell plasticity. AXL, a member of the TAM (Tyro3, Axl, and M…
View article: Supplementary Table S2 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Supplementary Table S2 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Open
Supplementary Table S2
View article: Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Data from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Open
Immune resistance may arise from both genetic instability and tumor heterogeneity. Microenvironmental stresses such as hypoxia and various resistance mechanisms promote carcinoma cell plasticity. AXL, a member of the TAM (Tyro3, Axl, and M…
View article: Supplementary Table S1 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Supplementary Table S1 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Open
Supplementary Table S1
View article: Supplementary Table S2 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Supplementary Table S2 from AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity Open
Supplementary Table S2
View article: Supplementary Figure S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 126KB, Analyses of two patients with detectable SF3B1 mutations in CD19+, CD34+ and CD14+ fractions.
View article: Supplementary Table S4 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S4 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 116KB, Association between acquired mutations (P values of Fisher's exact test for independence) among the 168 patients cohort.
View article: Supplementary Figure S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 170KB, Early mutations affect genes mutated in various human cancers (addition to the main text).
View article: Supplementary Table S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
XLS file - 336KB, Biological and clinical features of the 24 patients included in the whole-exome study.
View article: Data from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Data from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
Appropriate cancer care requires a thorough understanding of the natural history of the disease, including the cell of origin, the pattern of clonal evolution, and the functional consequences of the mutations. Using deep sequencing of flow…
View article: Supplementary Table S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
XLS file - 336KB, Biological and clinical features of the 24 patients included in the whole-exome study.
View article: Supplementary Table S5 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S5 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
XLS file - 75KB, Details of signature and expression analyses.
View article: Supplementary Table S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S2 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 211KB, Biological and clinical features of the 24 patients included in the whole-exome study.
View article: Data from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Data from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
Appropriate cancer care requires a thorough understanding of the natural history of the disease, including the cell of origin, the pattern of clonal evolution, and the functional consequences of the mutations. Using deep sequencing of flow…
View article: Supplementary Table S3 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S3 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 98KB, Biological and clinical features of the 168 CLL patients according to EGR2, NFKBIE and BRAF mutations.
View article: Supplementary Figure S3 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S3 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 136KB, Representative flow chart of the sorting procedure.
View article: Supplementary Figure S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Figure S1 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 126KB, Analyses of two patients with detectable SF3B1 mutations in CD19+, CD34+ and CD14+ fractions.
View article: Supplementary Table S4 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S4 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
PDF file - 116KB, Association between acquired mutations (P values of Fisher's exact test for independence) among the 168 patients cohort.
View article: Supplementary Table S5 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Supplementary Table S5 from Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients Open
XLS file - 75KB, Details of signature and expression analyses.